<!DOCTYPE html>
<html>
<head>
<title>Refpages</title>
<link rel="stylesheet" href="refstyle.css">
</head>

<body>

<!-- refpage 17---------------------------------------------------------------------------------------------------------->
<div class = "title">Vasolidatantia</div>

<div class = "source">
<div class = "quote">
Vasodilatantia: Nitraten, Alfa-blokkers<br>
Lijst van valrisico-verhogende medicaties (p 63)
</div><div class = "ref" name="1">
Nederlandse Vereniging voor Klinische Geriatrie. Preventie van valincidenten bij ouderen. <a href="https://richtlijnendatabase.nl/richtlijn/preventie_van_valincidenten_bij_ouderen/startpagina_-_preventie_van_valincidenten.html">https://richtlijnendatabase.nl/richtlijn/preventie_van_valincidenten_bij_ouderen/startpagina_-_preventie_van_valincidenten.html</a> Bezocht op 2020-07-01
</div>
</div>

<div class = "source">
<div class = "quote">
alfa-blockers used as antihypertensives<br>
Vasodilators used in cardiac diseases (Table 2: Fall-risk increasing drugs (FRIDs) according to the preliminary (September 2019) European consensus list.)
</div><div class = "quote">
Item 60: The patient is taking medication with a questionable efficacy and/or unfavourable safety profile e.g.: venotropic or vasodilatory drugs (e.g. cinnarizine, naftidrofuryl, pentoxifylline, piracetam). Questionable efficacy; Increased risk of adverse effects (e.g. orthostatic hypotension and falls) and interactions. 1st Re-evaluate whether indication is still present and prefer stopping therapy; 2nd Prefer non-pharmacological approach, a drug with a favourable risk/benefit ratio for a specified time, or refer to physician.
</div><div class="ref" name="7">
GheOP3S-tool draft 3 (2020-07-01)
</div>
</div>

<div class = "source">
<div class = "quote">
START/STOPP K3: vasodilatatoren (bijvoorbeeld a1-receptorblokkers, calciumantagonisten, langwerkende nitraten, ACE-remmers, angiotensine II-antagonisten) bij orthostatische hypotensie:
verhoogd risico op syncope, vallen
</div><div class="ref" name="9">
Wilma Knol, Monique M. Verduijn, A.C.A.M. (Rian) Lelie-van der Zande, Rob J. van Marum, J.R.B.J. (Koos) Brouwers, Tischa J.M. van der Cammen, Mirko Petrovic en Paul A.F. Jansen. Onjuist geneesmiddelgebruik bij ouderen opsporen: De herziene STOPP-en START-criteria. NED TIJDSCHR GENEESKD. 2015;159: A8904.
</div>
</div>

<div class = "source">
<div class = "quote">
(If there is) No valid indication ? Consider stopping the VD in stepwise manner: please see for possible strategies supplementary table 8.<br>
Safer alternatives available ? Change to safer alternative<br>
Lower dose has not been tried ? Try lower dose<br>
Otherwise ?Consider changing dosing time. (If) No safer alternative is available:  Perform a shared decision making with patient and possibly another specialist. Consider withdrawal if hypotension, OH, or dizziness present. Also, take patient goals into account.<br>
After withdrawal or dose reduction monitor for change in symptoms e.g., dizziness, and orthostatic hypotension, fall incidents and symptoms of angina pectoris.
Organize follow-ups individual basis based e.g. on patient history, and possible occurrence of symptoms.
</div><div class="ref" name="10">
L.J. Seppala, M. Petrovic, J. Ryg, G. Bahat, E. Topinkova, K. Szczerbinska, T.J.M. van der Cammen, S. Hartikainen, B. Ilhan, F. Landi, Y. Morrissey, A. Mair, M. Guti&eacute;rrez-Valencia, M.H. Emmelot-Vonk, M.A. Caballero Mora, M. Denkinger, P. Crome, S.H.D. Jackson, A. Correa-P&eacute;rez, W. Knol, G. Soulis, A. Gudmundsson, G. Ziere, M. Wehling, D. O</q>Mahony, A. Cherubini, N. van der Velde. STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk): a Delphi study by the EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs. Age & Aging (in process).
</div>
</div>



</body>